Opinion|Videos|October 25, 2024
Management of Relapsed/Refractory Multiple Myeloma with Bispecifics: MonumenTAL-2, MajesTEC-1, and MagnetisMM-3 trials
Panelists discuss recent updates in the management of relapsed/refractory multiple myeloma, focusing on key studies such as MonumenTAL-2 for talquetamab, long-term follow-up data from the phase 1/2 MajesTEC-1 for teclistamab, and findings from MagnetisMM-3 regarding elranatamab.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Comment on the recent updates surrounding the management of R/R MM with bispecifics and bispecific combination therapies:
- MonumenTAL-2 for talquetamab (
Schinke CD et al. ASCO 2023 Abstract 8036 ) - Long-term follow-up from the phase 1/2 MajesTEC-1 for teclistamab (
Garfall et al. ASCO 2024 Abstract 7540 ) - MagnetisMM-3for elranatamab in R/R MM (
Lesokhin A, Nature 2023 )
Advertisement
Related to this article
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment selection.
T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.
Data from the phase 3 EMBER-3 trial support the full approval of imlunestrant plus abemaciclib in this breast cancer population.
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
The European Medicines Agency’s CHMP recommended approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer based on the ROSELLA trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
2
Screening for CHIP Mutations to Guide CAR T Cell Candidacy in Lymphoma
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Daraxonrasib Receives FDA Breakthrough Therapy Status in 1L Metastatic PDAC
5